{
    "nctId": "NCT05107388",
    "briefTitle": "Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer",
    "officialTitle": "AAREN: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Diabetes",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Incidence rate of hyperglycemia",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women suffering breast cancer and eligible to treatment with Alpelisib\n2. Age \u226518 years\n3. Menopausal women (for at least 24 months)\n4. Informed Consent Form signed\n\nExclusion Criteria:\n\n1. Men\n2. Pregnant ou child-bearing potential women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}